arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Surrozen, Inc./DE

SRZN
$16.22 ▼ -1.30 (-7.42%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
27 Visible periods
23 Metrics
Peer-ranked Benchmarks
Price Chart
79
Health
Good
Bullish
auto_awesome

Analytical Summary

Surrozen, Inc./DE shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $189.2M
Dividend Yield —
Revenue Growth 408.6% →
Op. Margin -207.4% →
ROIC 3.7% ↗
FCF / Share $-0.64
Trailing P/E 5.9x
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$5.00M
↑ +408.6% —
Net Income Profit after all expenses
$50.18M
↑ +26.2% —
Operating Margin Operating profit as % of sales
-207.4%
↑ +0.8% —
FCF / Share Free cash flow per share
$-0.64
↑ +11.2% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
100
Cash Quality ↓
27

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters